A fortuitous enhancement of its approach to quality assessments launched by the US Food and Drug Administration’s Office of Pharmaceutical Quality over the holidays in December 2019 played a key role in enabling the office to keep up with the whirlwind of activity brought on by the coronavirus pandemic, OPQ director Michael Kopcha told the Pink Sheet.
Another key factor: people put in a lot of extra hours.








